Skip to main navigation
Skip to search
Skip to main content
University of Copenhagen Research Portal Home
Help & FAQ
Dansk
English
Home
Profiles
Research output
Research units
Press/Media
Activities
Prizes
???studenttheses???
Datasets
Search by expertise, name or affiliation
Antithrombin III for critically ill patients
Mikkel Allingstrup
*
, Jørn Wetterslev, Frederikke B Ravn,
Ann Merete Møller
,
Arash Afshari
*
Corresponding author for this work
Department of Clinical Medicine
23
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Antithrombin III for critically ill patients'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Antithrombin III (ATIII)
100%
Critically Ill Patients
100%
I2 Statistic
93%
Risk Ratio
62%
Fixed Effects Model
56%
Risk of Bias
31%
Random Effects Model
31%
Subgroup Analysis
25%
Disseminated Intravascular Coagulation
25%
Bleeding Events
18%
Trial Interventions
18%
Confidence Interval
18%
Sepsis
18%
Heparin
18%
Randomized Controlled Trial
18%
Multiple Organ Failure
12%
High Risk
12%
Severe Sepsis
12%
Ovid
12%
Intensive Care Unit
12%
Critically Ill
12%
Intervention Effect
12%
Length of Stay
12%
Trauma
6%
Embase
6%
Anti-inflammatory Properties
6%
Bleeding Risk
6%
Publication Status
6%
Missing Data
6%
Ventilation Rate
6%
Primary Outcome Measure
6%
Significant Benefit
6%
Anticoagulants
6%
Pediatric
6%
Red Blood Cells
6%
Chronic Conditions
6%
MEDLINE
6%
Respiratory Failure
6%
Obstetrics
6%
Outcome Analysis
6%
Critical Illness
6%
Health Assessment
6%
Review Update
6%
Sensitivity Analysis
6%
Inclusion Criteria
6%
Acute Physiology
6%
Vascular Damage
6%
Cochrane Central Register of Controlled Trials
6%
Search Methods
6%
Absence of Evidence
6%
Length of Follow-up
6%
Length of Hospital Stay
6%
Selection Criteria
6%
Low Risk
6%
CINAHL
6%
Uncontrolled Inflammation
6%
Dichotomous Outcomes
6%
Ongoing Trials
6%
Evaluation Score
6%
Harmful Effects
6%
Bleeding
6%
Clinical Analysis
6%
Number of Participants
6%
Patient Use
6%
Medicine and Dentistry
Antithrombin III
100%
Sepsis
31%
Random Effects Model
31%
Disseminated Intravascular Coagulation
25%
Subgroup Analysis
25%
Randomized Controlled Trial
18%
Heparin
18%
Intervention Trial
18%
Intensive Care Unit
12%
Multiple Organ Dysfunction Syndrome
12%
Obstetrics
6%
Blood Vessel Injury
6%
Sequential Analysis
6%
Supplementation
6%
Pediatrics
6%
APACHE II
6%
Critical Illness
6%
Injury
6%
Anti-Inflammatory Drug
6%
Erythrocyte
6%
Respiratory Failure
6%
Antithrombotic
6%
Artificial Respiration
6%
Nursing and Health Professions
Antithrombin III
100%
Sepsis
31%
Disseminated Intravascular Clotting
25%
Confidence Interval
18%
Length of Stay
18%
Heparin
18%
Multiple Organ Failure
12%
Intensive Care Unit
12%
Anticoagulant Agent
6%
Artificial Respiration
6%
Cochrane Library
6%
Inflammation
6%
CINAHL
6%
APACHE
6%
Critical Illness
6%
Supplementation
6%
Injury
6%
Respiratory Failure
6%
Blood Vessel Injury
6%
Sequential Analysis
6%
Pharmacology, Toxicology and Pharmaceutical Science
Antithrombin III
100%
Sepsis
31%
Random Effects Model
31%
Disseminated Intravascular Clotting
25%
Randomized Controlled Trial
18%
Intervention Trial
18%
Heparin
18%
Multiple Organ Failure
12%
Injury
6%
Respiratory Failure
6%
Inflammation
6%
Anti-Inflammatory Drug
6%
Blood Vessel Injury
6%
Anticoagulant Agent
6%
Critical Illness
6%